Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

Abstract Background Tolvaptan slows kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) who are at risk of rapid progression. Given that treatment requires commitment to long-term use, we evaluated the effects of tolvaptan discontinuation on the trajectory o...

Full description

Bibliographic Details
Main Authors: Michael Lioudis, Xiaolei Zhou, Eric Davenport, Sasikiran Nunna, Holly B. Krasa, Dorothee Oberdhan, Ancilla W. Fernandes
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Nephrology
Subjects:
Autosomal dominant polycystic kidney disease (ADPKD)
Tolvaptan
Glomerular filtration rate
Kidney volume
Clinical trial
Treatment
Online Access:https://doi.org/10.1186/s12882-023-03247-6

Internet

https://doi.org/10.1186/s12882-023-03247-6

Similar Items